These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 10470087

  • 21. Expression of three proopiomelanocortin subtype genes and mass spectrometric identification of POMC-derived peptides in pars distalis and pars intermedia of barfin flounder pituitary.
    Takahashi A, Amano M, Amiya N, Yamanome T, Yamamori K, Kawauchi H.
    Gen Comp Endocrinol; 2006 Feb; 145(3):280-6. PubMed ID: 16242690
    [Abstract] [Full Text] [Related]

  • 22. Integrated control of appetite and fat metabolism by the leptin-proopiomelanocortin pathway.
    Forbes S, Bui S, Robinson BR, Hochgeschwender U, Brennan MB.
    Proc Natl Acad Sci U S A; 2001 Mar 27; 98(7):4233-7. PubMed ID: 11259669
    [Abstract] [Full Text] [Related]

  • 23. Monitoring neuropeptide-specific proteases: processing of the proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in the skin.
    König S, Luger TA, Scholzen TE.
    Exp Dermatol; 2006 Oct 27; 15(10):751-61. PubMed ID: 16984256
    [Abstract] [Full Text] [Related]

  • 24. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
    Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H.
    N Engl J Med; 2016 Jul 21; 375(3):240-6. PubMed ID: 27468060
    [Abstract] [Full Text] [Related]

  • 25. The effects of proopiomelanocortin deficiency on murine adrenal development and responsiveness to adrenocorticotropin.
    Coll AP, Challis BG, Yeo GS, Snell K, Piper SJ, Halsall D, Thresher RR, O'Rahilly S.
    Endocrinology; 2004 Oct 21; 145(10):4721-7. PubMed ID: 15231703
    [Abstract] [Full Text] [Related]

  • 26. Hypothalamic POMC deficiency increases circulating adiponectin despite obesity.
    Yu H, Chhabra KH, Thompson Z, Jones GL, Kiran S, Shangguan G, Low MJ.
    Mol Metab; 2020 May 21; 35():100957. PubMed ID: 32244188
    [Abstract] [Full Text] [Related]

  • 27. Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1-28 to Pomc-/- mice reduces food intake and weight but does not affect adrenal growth or corticosterone production.
    Coll AP, Fassnacht M, Klammer S, Hahner S, Schulte DM, Piper S, Tung YC, Challis BG, Weinstein Y, Allolio B, O'Rahilly S, Beuschlein F.
    J Endocrinol; 2006 Aug 21; 190(2):515-25. PubMed ID: 16899584
    [Abstract] [Full Text] [Related]

  • 28. The central melanocortin system as a treatment target for obesity and diabetes: A brief overview.
    Goit RK, Taylor AW, Lo ACY.
    Eur J Pharmacol; 2022 Jun 05; 924():174956. PubMed ID: 35430211
    [Abstract] [Full Text] [Related]

  • 29. Obesity, diabetes and functions for proopiomelanocortin-derived peptides.
    Mountjoy KG, Wong J.
    Mol Cell Endocrinol; 1997 Apr 04; 128(1-2):171-7. PubMed ID: 9140088
    [Abstract] [Full Text] [Related]

  • 30. [POMC gene mutations in human].
    Onigata K, Ogawa Y.
    Nihon Rinsho; 2006 Sep 28; Suppl 3():255-9. PubMed ID: 17022541
    [No Abstract] [Full Text] [Related]

  • 31. A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in pomc null mice.
    Tung YC, Piper SJ, Yeung D, O'Rahilly S, Coll AP.
    Endocrinology; 2006 Dec 28; 147(12):5940-7. PubMed ID: 16959830
    [Abstract] [Full Text] [Related]

  • 32. Impaired neonatal survival of pro-opiomelanocortin null mutants.
    Saedler K, Hochgeschwender U.
    Mol Cell Endocrinol; 2011 Apr 10; 336(1-2):6-13. PubMed ID: 21184805
    [Abstract] [Full Text] [Related]

  • 33. From Agouti to Pomc--100 years of fat blonde mice.
    Barsh G.
    Nat Med; 1999 Sep 10; 5(9):984-5. PubMed ID: 10470066
    [No Abstract] [Full Text] [Related]

  • 34. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT.
    Mol Metab; 2017 Oct 10; 6(10):1321-1329. PubMed ID: 29031731
    [Abstract] [Full Text] [Related]

  • 35. A case of early-onset obesity, hypocortisolism, and skin pigmentation problem due to a novel homozygous mutation in the proopiomelanocortin (POMC) gene in an Indian boy.
    Hung CN, Poon WT, Lee CY, Law CY, Chan AY.
    J Pediatr Endocrinol Metab; 2012 Oct 10; 25(1-2):175-9. PubMed ID: 22570972
    [Abstract] [Full Text] [Related]

  • 36. 60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH.
    Anderson EJ, Çakir I, Carrington SJ, Cone RD, Ghamari-Langroudi M, Gillyard T, Gimenez LE, Litt MJ.
    J Mol Endocrinol; 2016 May 10; 56(4):T157-74. PubMed ID: 26939593
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P, Setmelanotide POMC and LEPR Phase 3 Trial Investigators.
    Lancet Diabetes Endocrinol; 2020 Dec 10; 8(12):960-970. PubMed ID: 33137293
    [Abstract] [Full Text] [Related]

  • 38. Lack of proopiomelanocortin peptides results in obesity and defective adrenal function but normal melanocyte pigmentation in the murine C57BL/6 genetic background.
    Smart JL, Low MJ.
    Ann N Y Acad Sci; 2003 Jun 10; 994():202-10. PubMed ID: 12851317
    [Abstract] [Full Text] [Related]

  • 39. Pro-opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortin-1 receptor-independent pathway.
    Tsai HE, Liu LF, Dusting GJ, Weng WT, Chen SC, Kung ML, Tee R, Liu GS, Tai MH.
    J Gene Med; 2012 Jan 10; 14(1):44-53. PubMed ID: 22147647
    [Abstract] [Full Text] [Related]

  • 40. Implications of the phenotype of POMC deficiency for the role of POMC-derived peptides in skin physiology.
    Krude H, Schnabel D, Luck W, Grüters A.
    Ann N Y Acad Sci; 1999 Oct 20; 885():419-21. PubMed ID: 10816678
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.